Cutter Capital Management LP Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Cutter Capital Management LP has reduced its stake in Ultragenyx Pharmaceutical by 6.8%, owning 379,303 shares after selling 27,500 shares in the first quarter.
• Ultragenyx Pharmaceutical reported its quarterly earnings with a loss of ($1.17) EPS, exceeding the consensus estimate of (1.27), and revenues of $166.50 million, which was also above expectations.
• As of now, 97.67% of Ultragenyx Pharmaceutical's stock is owned by institutional investors, highlighting significant institutional interest in the company.

Cutter Capital Management LP cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 379,303 shares of the biopharmaceutical company's stock after selling 27,500 shares during the period. Ultragenyx Pharmaceutical comprises 6.0% of Cutter Capital Management LP's holdings, making the stock its 6th largest holding. Cutter Capital Management LP owned approximately 0.40% of Ultragenyx Pharmaceutical worth $13,735,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 323 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at approximately $57,000. Headlands Technologies LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at approximately $59,000. Covestor Ltd increased its position in shares of Ultragenyx Pharmaceutical by 86.8% during the 1st quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock valued at $62,000 after purchasing an additional 795 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at approximately $82,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Stock Down 1.5%

RARE opened at $31.55 on Thursday. The stock's fifty day moving average is $30.61 and its two-hundred day moving average is $35.02. The company has a market capitalization of $3.04 billion, a P/E ratio of -5.71 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. The company had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.Ultragenyx Pharmaceutical's quarterly revenue was up 13.2% on a year-over-year basis. During the same period last year, the business posted ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. William Blair assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective on the stock. HC Wainwright upgraded shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price target on the stock in a report on Monday, July 28th. Morgan Stanley cut their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. Guggenheim reaffirmed a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Finally, Wedbush cut their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research report on Monday, July 14th. Eleven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average price target of $81.50.

Insider Activity at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director owned 15,344 shares in the company, valued at approximately $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.